Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II).
Ogawa Y, Kubota K, Ue H, Kataoka Y, Tadokoro M, Miyatake K, Tsuzuki K, Yamanishi T, Itoh S, Hitomi J, Hamada N, Kariya S, Fukumoto M, Nishioka A, Inomata T. Ogawa Y, et al. Among authors: yamanishi t. Int J Oncol. 2009 Mar;34(3):609-18. doi: 10.3892/ijo_00000186. Int J Oncol. 2009. PMID: 19212665 Clinical Trial.
Therapeutic response to a novel enzyme-targeting radiosensitization treatment (Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas) in patients with recurrent breast cancer.
Aoyama N, Ogawa Y, Yasuoka M, Takahashi M, Iwasa H, Miyatake K, Yamanishi T, Hamada N, Tamura T, Nishioka A, Yamagami T. Aoyama N, et al. Among authors: yamanishi t. Oncol Lett. 2016 Jul;12(1):29-34. doi: 10.3892/ol.2016.4589. Epub 2016 May 16. Oncol Lett. 2016. PMID: 27347095 Free PMC article.
Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane.
Aoyama N, Ogawa Y, Yasuoka M, Iwasa H, Miyatake K, Yoshimatsu R, Yamanishi T, Hamada N, Tamura T, Kobayashi K, Murata Y, Yamagami T, Miyamura M. Aoyama N, et al. Among authors: yamanishi t. Oncol Lett. 2017 Jan;13(1):69-76. doi: 10.3892/ol.2016.5456. Epub 2016 Dec 1. Oncol Lett. 2017. PMID: 28123524 Free PMC article.
Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi oxydol-radiation therapy for unresectable carcinomas II, in patients with stage I primary breast cancer.
Aoyama N, Ogawa Y, Yasuoka M, Ohgi K, Iwasa H, Miyatake K, Yoshimatsu R, Yamanishi T, Hamada N, Tamura T, Kobayashi K, Murata Y, Miyamura M, Yamagami T. Aoyama N, et al. Among authors: yamanishi t. Oncol Lett. 2017 Jun;13(6):4741-4747. doi: 10.3892/ol.2017.6074. Epub 2017 Apr 21. Oncol Lett. 2017. PMID: 28599475 Free PMC article.
391 results